News

Life sciences startup secures $30 million and opens Fulton Market lab
The expansion is a good signal for an industry that slowed down, both in Chicago and nationwide, as interest rates rose and ...
Pittsburgh biotech firms benefit in potential pharma tariffs and domestic manufacturing shift
Pittsburgh biotech firms see potential benefits from upcoming tariffs and reshoring efforts, despite uncertainties in NIH ...
Dosing begins in Tiziana Life Sciences’ trial of foralumab for na-SPMS
Tiziana Life Sciences has announced the commencement of dosing in the fourth clinical site of the company’s Phase II trial of ...
Tiziana Life Sciences announces UMass commences Phase 2 na-SPMS trial
Tiziana Life Sciences (TLSA) announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal ...
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
From Lab to Unicorn: Xlife Sciences AG Portfolio Company VERAXA Biotech AG to merge with Voyager Acquisition Corp. listed on NASDAQ
The proposed transaction values VERAXA Biotech AG at USD 1.64 billion with expected gross cash proceeds up to USD 253 million held in trust by Voyager Acquisition Corp.